Comparison of enoxaparin 40 mg versus 60 mg dosage for venous thromboprophylaxis in patients undergoing bariatric surgery: A randomized controlled trial
CONCLUSIONS: A 60 mg of enoxaparin regimen achieved more prophylactic anti-factor Xa levels than 40 mg in obese patients undergoing bariatric surgery without any adverse events.PMID:38514281 | DOI:10.1016/j.asjsur.2024.02.095 (Source: Asian Journal of Surgery)
Source: Asian Journal of Surgery - March 21, 2024 Category: Surgery Authors: Kritsada Kongsawat Komol Chaivanijchaya Fon Pakul Suthikiat Joradol Pattharasai Kachornvitaya Patchaya Boonchaya-Anant Suthep Udomsawaengsup Source Type: research
Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study
This study examines the safety and efficacy of using peak anti-Xa levels to achieve prophylactic enoxaparin (Lovenox, Sanofi-Aventis) levels in patients who underwent hepatic surgery. Prospectively enrolled patients undergoing major and minor hepatic procedures received postoperative enoxaparin dosing. The enoxaparin dose was adjusted to attain a peak anti-Xa level ≥ 0.20 U/ml. This group was compared to a historical cohort of patients who underwent similar procedures and received standard postoperative VTE chemoprophylaxis dosing. Inpatient postoperative VTE rates were higher in the control group when compared to the ex...
Source: The American Surgeon - March 15, 2024 Category: Surgery Authors: Samuel Coster Ali Shammout Michael Chaney Kyra Folkert Kent Grosh Saad Shebrain Gitonga Munene Source Type: research
Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study
This study examines the safety and efficacy of using peak anti-Xa levels to achieve prophylactic enoxaparin (Lovenox, Sanofi-Aventis) levels in patients who underwent hepatic surgery. Prospectively enrolled patients undergoing major and minor hepatic procedures received postoperative enoxaparin dosing. The enoxaparin dose was adjusted to attain a peak anti-Xa level ≥ 0.20 U/ml. This group was compared to a historical cohort of patients who underwent similar procedures and received standard postoperative VTE chemoprophylaxis dosing. Inpatient postoperative VTE rates were higher in the control group when compared to the ex...
Source: The American Surgeon - March 15, 2024 Category: Surgery Authors: Samuel Coster Ali Shammout Michael Chaney Kyra Folkert Kent Grosh Saad Shebrain Gitonga Munene Source Type: research
Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study
This study examines the safety and efficacy of using peak anti-Xa levels to achieve prophylactic enoxaparin (Lovenox, Sanofi-Aventis) levels in patients who underwent hepatic surgery. Prospectively enrolled patients undergoing major and minor hepatic procedures received postoperative enoxaparin dosing. The enoxaparin dose was adjusted to attain a peak anti-Xa level ≥ 0.20 U/ml. This group was compared to a historical cohort of patients who underwent similar procedures and received standard postoperative VTE chemoprophylaxis dosing. Inpatient postoperative VTE rates were higher in the control group when compared to the ex...
Source: The American Surgeon - March 15, 2024 Category: Surgery Authors: Samuel Coster Ali Shammout Michael Chaney Kyra Folkert Kent Grosh Saad Shebrain Gitonga Munene Source Type: research
Prophylactic Enoxaparin Dosing Using Anti-Factor Xa Levels in Hepatic Surgery Patients: A Pilot Study
This study examines the safety and efficacy of using peak anti-Xa levels to achieve prophylactic enoxaparin (Lovenox, Sanofi-Aventis) levels in patients who underwent hepatic surgery. Prospectively enrolled patients undergoing major and minor hepatic procedures received postoperative enoxaparin dosing. The enoxaparin dose was adjusted to attain a peak anti-Xa level ≥ 0.20 U/ml. This group was compared to a historical cohort of patients who underwent similar procedures and received standard postoperative VTE chemoprophylaxis dosing. Inpatient postoperative VTE rates were higher in the control group when compared to the ex...
Source: The American Surgeon - March 15, 2024 Category: Surgery Authors: Samuel Coster Ali Shammout Michael Chaney Kyra Folkert Kent Grosh Saad Shebrain Gitonga Munene Source Type: research
Enoxaparin-sodium
(Source: Reactions Weekly)
Source: Reactions Weekly - March 1, 2024 Category: Drugs & Pharmacology Source Type: research
Safety and Efficacy of Enoxaparin During Low-Risk Elective Percutaneous Coronary Intervention
Intravenous unfractionated heparin (UFH) is the most frequently used anticoagulant for percutaneous coronary intervention (PCI). Intravenous enoxaparin, a low-molecular weight heparin, has superior pharmacokinetic and pharmacodynamic properties compared with UFH. Multiple trials have shown enoxaparin to be safe and effective in PCI. However, there has not been a contemporary study evaluating its safety and efficacy. To assess its efficacy and safety, intravenous enoxaparin during PCI via radial artery access was evaluated in PCI patients from Jan 2015 to Dec 2019. (Source: The American Journal of Cardiology)
Source: The American Journal of Cardiology - February 29, 2024 Category: Cardiology Authors: Hani Alturkmani, Barry Uretsky, Swetal Patel, Mu'nes Albadaineh, Omar Alqaisi, Malek Alaiwah, Michael Cross, Danish Abbasi, William Rollefson Source Type: research
Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial
CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03664180.PMID:38406848 | DOI:10.1161/CIRCULATIONAHA.123.067079 (Source: Circulation)
Source: Circulation - February 26, 2024 Category: Cardiology Authors: Yan Yan Jincheng Guo Xiao Wang Guozhong Wang Zeyuan Fan Delu Yin Zhifang Wang Fuchun Zhang Changming Tian Wei Gong Jiamin Liu Jiapeng Lu Yongjun Li Changsheng Ma Eric Vicaut Gilles Montalescot Shaoping Nie RIGHT Investigators Source Type: research
Postprocedural Anticoagulation After Primary Percutaneous Coronary Intervention for ST-Segment-Elevation Myocardial Infarction: A Multicenter, Randomized, Double-Blind Trial
CONCLUSIONS: Routine PPA after primary percutaneous coronary intervention was safe but did not reduce 30-day ischemic events.REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03664180.PMID:38406848 | DOI:10.1161/CIRCULATIONAHA.123.067079 (Source: Circulation)
Source: Circulation - February 26, 2024 Category: Cardiology Authors: Yan Yan Jincheng Guo Xiao Wang Guozhong Wang Zeyuan Fan Delu Yin Zhifang Wang Fuchun Zhang Changming Tian Wei Gong Jiamin Liu Jiapeng Lu Yongjun Li Changsheng Ma Eric Vicaut Gilles Montalescot Shaoping Nie RIGHT Investigators Source Type: research
Enoxaparin is safe for the treatment of venous thromboembolisms in patients with renal dysfunction: A retrospective cohort study
Unfractionated heparin (UFH) and low molecular weight heparins (LMWH), such as enoxaparin, are commonly used anticoagulants for the prevention and treatment of venous thromboembolisms. Several studies have compared their safety and efficacy, including a meta-analysis that showed them to be similarly efficacious with no difference in bleeding risk [1]. While UFH has been used in practice longer, LMWH offers a more predictable pharmacokinetic profile and requires less laboratory monitoring. (Source: Thrombosis Research)
Source: Thrombosis Research - February 26, 2024 Category: Hematology Authors: Connor Flynn, Julie Baldassarra, Arzo Hamidi Tags: Letter to the Editors-in-Chief Source Type: research
A systematic review of therapeutic enoxaparin dosing in obesity
AbstractEnoxaparin is a hydrophilic drug with obesity having little effect on its apparent volume of distribution, therefore patients with obesity receiving standard 1 mg/kg dosing may be at a higher risk of supratherapeutic dosing. Conversely, dose reducing patients with obesity could place already at risk patients at higher risk of a thrombotic event. Data and recommendations are variable for the most appropriate weight-based dose of therapeutic enoxaparin in obese patients, particularly those a weight > 100 kg or a body mass index (BMI) ≥ 40 kg/m2. The purpose of this systematic review was to globally ...
Source: Journal of Thrombosis and Thrombolysis - February 25, 2024 Category: Hematology Source Type: research
A ten-year comparison of treatment and outcomes of cancer-associated thrombosis to non-cancer venous thromboembolism: from traditional anticoagulants to direct oral anticoagulants
This study demonstrated no significant differences in complication rates for CAT patients treated with DOAC s over enoxaparin, suggesting that DOACs can be safely used in most cases of CAT. (Source: Journal of Thrombosis and Thrombolysis)
Source: Journal of Thrombosis and Thrombolysis - February 23, 2024 Category: Hematology Source Type: research
